A recent in the Journal of Personalized Medicine, “Mineralocorticoid Receptor Antagonists and Cognitive Outcomes in Cardiovascular Disease and Beyond: A Systematic Review" showcases an important research collaboration between the Division of Cardiology in the 51±¬ÁÏÍø of Medicine at Stony Brook University and Columbia University in the City of New York.
First author Paolo Pastena, PhD, was a recent postdoctoral researcher in the Division of Cardiology, and is now a postdoc at Columbia. Ali Reza Rahmani, PhD, is a current postdoc within the cardiology division, and Gabriele Campagnoli, PhD, is a current postdoc at Columbia, working with Dr. Pastena. The study was guided by Dr. Andreas Kalogeropoulos, MD MPH PhD, Associate Professor of Medicine and Director of Research of the Heart Institute at Stony Brook.
The following outline explains the objectives of this publication:
"Cognitive impairment is a debilitating comorbidity affecting diverse patient populations, yet the cognitive effects of therapies like mineralocorticoid receptor antagonists (MRAs) remain underexplored. Preclinical evidence suggests that MRAs, particularly spironolactone, may reduce cognitive decline by modulating aldosterone-dependent pathways and targeting hippocampal receptors. However, evidence in humans is fragmented, and no systematic review has consolidated these findings. This review evaluates the cognitive effects of MRAs, synthesizes current data, and identifies research gaps."
co
Congratulations to the researchers in the Division of Cardiology and Columbia University on this important research that highlights how spironolactone exhibits potential cognitive benefits across diverse populations.